This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Genentech's Avastin Passes Key Safety Test

Genentech (DNA) said late Thursday that its late-stage trial on Avastin in early-stage colon cancer patients passed a recent safety check and it now expects final data a year earlier than previously thought.

The South San Francisco-based company said that final efficacy and safety results for the C-08 study will now be available in 2009, rather than 2010, because of speedy data collection, patient enrollment and a higher than planned number of Stage III patients. The phase III, 2,700 patient study - which is being conducted by the National Surgical Adjuvant Breast and Bowel Project (NSABP) -- is looking at Avastin plus chemotherapy compared to the chemotherapy alone following surgery in the early-stage colon cancer patient population.

Genentech said the new timeline doesn't affect its probability of success. In conjunction with the release of abstracts for the American Society of Clinical Oncology annual meeting, the company also announced that the C-08 study received a green light from an independent data monitoring committee that conducted an interim safety and efficacy analysis in the second quarter of this year.

The board found no new or unexpected safety events in the Avastin arm in the interim check. "Due to the high cure rate for early-stage colon cancer, there is a lower acceptance of risk related to potential new therapies in the adjuvant treatment setting," said Genentech senior vice president (Clinical Hematology and Oncology) David Schenkein in a press release Thursday.

The preliminary analysis showed a similar rate of non-cancer-related deaths between the treatment arms, which was consistent with previous trials, according to the company. "Grade 3" or higher events that occurred more in the Avastin plus chemotherapy arm included hypertension, wound healing complications and pain. The company will present the safety report on Saturday, May 31 at the ASCO meeting.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
IMCL $3.00 -44.44%
AMGN $163.58 -1.97%
CELG $113.47 -2.48%
AAPL $124.75 -1.13%
FB $80.78 -1.86%

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs